Biotech Values

[DewDiligence]

GILD—[Wells]: Summing up Harvoni and Sovaldi, new prescriptions for GILD's HCV franchise were 2,127, up 16% week over week. We believe this confirms the potential for Harvoni to re-accelerate prescription growth and draw increasing numbers of patients onto therapy.

This is oddly banal (even for a sell-side analyst)! Clearly, Harvoni is a better option for patients than any HCV regimen containing standalone Sovaldi, so it’s hardly surprising that the sum of Harvoni and Sovaldi scripts has increased. This sum will almost certainly continue increasing until competition hits the market in the next couple of months.